Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C54H92O23 |
Molecular Weight | 1109.2945 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 30 / 30 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]3([H])[C@@]4(C)CC[C@H](O[C@]5([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@]6([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(C)(C)[C@]4([H])CC[C@@]23C)[C@](C)(CCC=C(C)C)O[C@@H]7O[C@H](CO[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@@H](O)[C@H](O)[C@H]7O
InChI
InChIKey=GZYPWOGIYAIIPV-JBDTYSNRSA-N
InChI=1S/C54H92O23/c1-23(2)10-9-14-54(8,77-48-44(69)40(65)37(62)29(74-48)22-70-46-42(67)38(63)34(59)26(19-55)71-46)24-11-16-53(7)33(24)25(58)18-31-51(5)15-13-32(50(3,4)30(51)12-17-52(31,53)6)75-49-45(41(66)36(61)28(21-57)73-49)76-47-43(68)39(64)35(60)27(20-56)72-47/h10,24-49,55-69H,9,11-22H2,1-8H3/t24-,25+,26+,27+,28+,29+,30-,31+,32-,33-,34+,35+,36+,37+,38-,39-,40-,41-,42+,43+,44+,45+,46+,47-,48-,49-,51-,52+,53+,54-/m0/s1
Molecular Formula | C54H92O23 |
Molecular Weight | 1109.2945 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 30 / 30 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: Description was created based on several sources, including https://www.lktlabs.com/product/ginsenoside-rb1/
https://www.ncbi.nlm.nih.gov/pubmed/25120573
Curator's Comment: Description was created based on several sources, including https://www.lktlabs.com/product/ginsenoside-rb1/
https://www.ncbi.nlm.nih.gov/pubmed/25120573
Ginsenoside Rb1 is a triterpene saponin originally found in species of Panax that exhibits antioxidative, anti-inflammatory, neuroprotective, orexigenic, and stimulatory activities. In animal models, ginsenoside Rb1 increases motor activity, food intake, and skeletal muscle ATP content, improving energy metabolism. Ginsenoside Rb1 also downregulates expression of toll-like receptor 4 (TLR4) and TNF-α in animal models of sepsis, protecting against liver and lung damage. Additionally, ginsenoside Rb1 inhibits glucose-induced neurotoxicity by preventing GSK-3β-stimulated CHOP induction. This compound also activates Nrf2 and increases expression of heme oxygenase 1 (HO-1), suppressing oxidative stress in vitro. Ginsenoside Rb1 improves learning and memory, increases Bmax of M-cholinergic receptors, and accelerates cerebral protein and ACh biosynthesis. Ginsenoside Rb1 is a component of Korean Red Ginseng, marketed in Korea. Korean ginseng (Panax ginseng Meyer, Araliaceae) is traditionally used as an important herbal medicine in Far East Asia. Korean Red Ginseng is possibly effective for:
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27060612 | https://www.ncbi.nlm.nih.gov/pubmed/15663889
Curator's Comment: Ginsenoside Rb1 improves learning and memory, increases Bmax of M-cholinergic receptors, and accelerates cerebral protein and ACh biosynthesis.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0006915 |
|||
Target ID: GLP1 secretion Sources: https://www.ncbi.nlm.nih.gov/pubmed/23444389 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of the ginsenosides Rg1 and Rb1 on morphine-induced hyperactivity and reinforcement in mice. | 1998 May |
|
Inhibition by ginsenosides Rb1 and Rg1 of methamphetamine-induced hyperactivity, conditioned place preference and postsynaptic dopamine receptor supersensitivity in mice. | 1998 May |
|
Inhibition by ginsenosides Rb1 and Rg1 of cocaine-induced hyperactivity, conditioned place preference, and postsynaptic dopamine receptor supersensitivity in mice. | 1999 Jul |
|
Ginsenoside-Rb1 acts as a weak phytoestrogen in MCF-7 human breast cancer cells. | 2003 Jan |
|
Calcium-independent CaMKII activity is involved in ginsenoside Rb1-mediated neuronal recovery after hypoxic damage. | 2005 Jan 14 |
|
Modulating effect of ginseng saponins on heterologously expressed HERG currents in Xenopus oocytes. | 2005 May |
|
Metabolism of ginsenoside Re by human intestinal microflora and its estrogenic effect. | 2005 Oct |
|
Efficient induction of ginsenoside biosynthesis and alteration of ginsenoside heterogeneity in cell cultures of Panax notoginseng by using chemically synthesized 2-hydroxyethyl jasmonate. | 2006 Apr |
|
Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. | 2006 Nov |
|
Protective effects of ginsenoside Rb1, ginsenoside Rg1, and notoginsenoside R1 on lipopolysaccharide-induced microcirculatory disturbance in rat mesentery. | 2007 Jul 19 |
|
Comparison of ginsenosides Rg1 and Rb1 for their effects on improving scopolamine-induced learning and memory impairment in mice. | 2010 Dec |
|
Ginsenoside Rb1 protects against 6-hydroxydopamine-induced oxidative stress by increasing heme oxygenase-1 expression through an estrogen receptor-related PI3K/Akt/Nrf2-dependent pathway in human dopaminergic cells. | 2010 Jan 1 |
|
Anti-diabetic effects of Panax notoginseng saponins and its major anti-hyperglycemic components. | 2010 Jul 20 |
|
Pharmacodynamics of ginsenosides: antioxidant activities, activation of Nrf2, and potential synergistic effects of combinations. | 2012 Aug 20 |
|
Ginsenoside Rb1 inhibits osteoclastogenesis by modulating NF-κB and MAPKs pathways. | 2012 May |
|
Protective effects of panax notoginseng saponins on cardiovascular diseases: a comprehensive overview of experimental studies. | 2014 |
|
Ginsenoside Re and Rd enhance the expression of cholinergic markers and neuronal differentiation in Neuro-2a cells. | 2014 |
|
Dissecting active ingredients of Chinese medicine by content-weighted ingredient-target network. | 2014 Jul |
|
Effects of Astragaloside IV combined with the active components of Panax notoginseng on oxidative stress injury and nuclear factor-erythroid 2-related factor 2/heme oxygenase-1 signaling pathway after cerebral ischemia-reperfusion in mice. | 2014 Oct |
|
Ginsenosides may enhance the functionality of human embryonic stem cell-derived cardiomyocytes in vitro. | 2014 Oct |
|
Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3. | 2015 Feb |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01761227
To treat vascular dementia:
Fufangdanshen tablet contains ginsenoside Rb1 3.03mg, as well as tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rg1 2.73mg. 3 tablets per time, 3 times per day for 24 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25120573
Compared with the control group, GS-Rb1 from 2.5 to 40 uM incubation increased viability of neonatal rat cardiomyocytes from 31.7%±1.3% to 53.3%±1.7%.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 02:15:47 GMT 2023
by
admin
on
Sat Dec 16 02:15:47 GMT 2023
|
Record UNII |
7413S0WMH6
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Ginsenoside Rb1
Created by
admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
|
PRIMARY | |||
|
7413S0WMH6
Created by
admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
|
PRIMARY | |||
|
310103
Created by
admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
|
PRIMARY | |||
|
DB06749
Created by
admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
|
PRIMARY | |||
|
9898279
Created by
admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
|
PRIMARY | |||
|
41753-43-9
Created by
admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
|
PRIMARY | |||
|
1291661
Created by
admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
|
PRIMARY | |||
|
DTXSID401316929
Created by
admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
|
PRIMARY | |||
|
67989
Created by
admin on Sat Dec 16 02:15:47 GMT 2023 , Edited by admin on Sat Dec 16 02:15:47 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
USP
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
USP
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
USP
|